Erasca shares climb as Street raises targets ahead of ERAS-0015 catalysts
Erasca (ERAS) is rising as investors position for a data-heavy 2026 centered on its lead pan-RAS program ERAS-0015, following recent bullish analyst target increases into the $20–$25 range. The move also follows fresh attention on insider selling disclosed for April 1, 2026, which appears to have been absorbed by buyers.
1) What’s moving ERAS today
Erasca shares are modestly higher in Thursday trading as momentum continues to build around the company’s lead pan-RAS molecular glue program, ERAS-0015, and the broader expectation for multiple 2026 clinical readouts. Recent sell-side notes have also helped support the tape, with targets recently lifted as the Street frames 2026 as a catalyst-rich year for ERAS-0015 and other pipeline assets.
2) The catalyst backdrop investors are trading
The stock’s advance comes after a sequence of positive setup events that have kept ERAS on biotech momentum screens: investor focus has centered on ERAS-0015’s clinical trajectory and expectations for additional data. Separately, the company’s earlier financing actions strengthened balance-sheet runway, reducing near-term dilution concerns for some investors and enabling a clearer “wait for data” trade into upcoming milestones.
3) What to watch next
Key swing factors over the coming weeks include any incremental trial enrollment updates, timing guidance around next presentations or data releases, and further changes in analyst targets as new information emerges. Traders will also watch for follow-through volume and any additional insider transactions that could influence sentiment around near-term positioning.